COSMOS Pharmaceutical Corporation (JP:3349)
:3349
Top Page
COSMOS Pharmaceutical Corporation
(3349)
Select Model
Select Model
Rating:60Neutral
Price Target:
¥7,118.00
▲(6.25% Upside)
Action:ReiteratedDate:10/16/25
The overall stock score of 60 reflects strong financial performance with robust revenue growth and profitability. However, technical indicators suggest bearish momentum, and the negative free cash flow trend is a concern. The valuation is reasonable, but the low dividend yield may not appeal to all investors.
Positive Factors
Consistent Revenue Growth
COSMOS has maintained a multi-year upward revenue trajectory, showing structural demand for its drugstore offerings. Durable top-line growth supports scale economies in purchasing and distribution, enabling reinvestment in stores and merchandising that underpin medium‑term earnings resiliency.
Negative Factors
Negative Free Cash Flow Trend
Despite strong operating cash generation, persistent negative free cash flow shows earnings are not fully converting to available cash after investments. Over time this can constrain dividends, capex funding, and deleveraging, forcing reliance on external financing or asset sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
COSMOS has maintained a multi-year upward revenue trajectory, showing structural demand for its drugstore offerings. Durable top-line growth supports scale economies in purchasing and distribution, enabling reinvestment in stores and merchandising that underpin medium‑term earnings resiliency.
Read all positive factors
COSMOS Pharmaceutical Corporation (3349) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥543.51B
Dividend Yield0.93%
Average Volume (3M)399.89K
Price to Earnings (P/E)22.8
Beta (1Y)-0.22
Revenue Growth3.73%
EPS Growth18.84%
CountryJP
Employees5,512
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)81.73
Shares Outstanding80,001,600
10 Day Avg. Volume586,980
30 Day Avg. Volume399,893
Financial Highlights & Ratios
PEG Ratio0.85
Price to Book (P/B)2.72
Price to Sales (P/S)0.69
P/FCF Ratio-814.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)398.41
Revenue Forecast (FY)¥1.09T
COSMOS Pharmaceutical Corporation Business Overview & Revenue Model
Company Description
COSMOS Pharmaceutical Corporation operates a chain of drug stores in Japan. It also operates 1,130 stores in the Kanto, Chubu, Kansai, Chugoku, Shikoku, and Kyushu regions. The company was founded in 1983 and is headquartered in Fukuoka, Japan....
How the Company Makes Money
COSMOS Pharmaceutical Corporation makes money mainly through retail sales in its drugstore operations. Its core revenue stream is product sales to consumers in physical stores, typically spanning (1) pharmaceuticals (including prescription dispens...
COSMOS Pharmaceutical Corporation Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
65
Positive
| Breakdown | May 2025 | May 2024 | May 2023 | May 2022 | May 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.01T | 964.99B | 827.70B | 755.41B | 726.42B |
| Gross Profit | 213.28B | 188.31B | 168.72B | 151.45B | 145.11B |
| EBITDA | 64.85B | 53.74B | 50.19B | 48.21B | 52.44B |
| Net Income | 30.98B | 24.45B | 23.80B | 23.16B | 27.16B |
Balance Sheet | |||||
| Total Assets | 525.17B | 476.98B | 421.41B | 363.50B | 341.78B |
| Cash, Cash Equivalents and Short-Term Investments | 57.04B | 52.30B | 45.93B | 37.36B | 55.11B |
| Total Debt | 49.96B | 34.06B | 18.20B | 9.41B | 10.44B |
| Total Liabilities | 267.71B | 245.53B | 210.33B | 172.99B | 171.20B |
| Stockholders Equity | 257.46B | 231.44B | 211.07B | 190.51B | 170.58B |
Cash Flow | |||||
| Free Cash Flow | -859.00M | -859.00M | -635.00M | 7.80B | -11.30B |
| Operating Cash Flow | 52.47B | 52.47B | 55.17B | 54.43B | 32.19B |
| Investing Cash Flow | -55.45B | -55.45B | -57.33B | -49.11B | -43.72B |
| Financing Cash Flow | 7.72B | 7.72B | 8.53B | 3.25B | -6.22B |
COSMOS Pharmaceutical Corporation Technical Analysis
Neutral
6699.00
Price Trends
6894.96
Negative
7220.57
Negative
7982.87
Negative
Market Momentum
-48.02
Negative
50.28
Neutral
49.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3349, the sentiment is Neutral. The current price of 6699 is below the 20-day moving average (MA) of 6712.85, below the 50-day MA of 6894.96, and below the 200-day MA of 7982.87, indicating a neutral trend. The MACD of -48.02 indicates Negative momentum. The RSI at 50.28 is Neutral, neither overbought nor oversold. The STOCH value of 49.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:3349.
COSMOS Pharmaceutical Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥684.54B | 23.29 | 15.71% | 0.96% | 21.81% | 67.76% | |
75 Outperform | ¥211.78B | 12.71 | ― | 2.35% | 7.55% | 16.01% | |
69 Neutral | ¥465.59B | 14.05 | 11.37% | 3.04% | 6.32% | 8.19% | |
67 Neutral | ¥1.12T | 25.31 | ― | 1.72% | ― | ― | |
67 Neutral | ¥373.38B | 20.79 | ― | 0.41% | 15.81% | 27.05% | |
60 Neutral | ¥543.51B | 22.79 | ― | 0.93% | 3.73% | 18.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
JP:3349
COSMOS Pharmaceutical Corporation
6,828.00
-856.37
-11.14%
JP:9989
Sundrug Co
3,982.00
-179.24
-4.31%
JP:7649
Sugi Holdings Co
3,632.00
825.85
29.43%
JP:3391
TSURUHA Holdings
2,489.50
560.75
29.07%
JP:3148
Create SD Holdings Co., Ltd.
3,350.00
586.13
21.21%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,905.00
965.88
32.86%
COSMOS Pharmaceutical Corporation Corporate Events
COSMOS Pharmaceutical Overhauls Organization, Launches Legal and Hotel Departments
Jan 13, 2026
COSMOS Pharmaceutical Corporation has announced a series of organizational and personnel changes effective February 1, 2026, aimed at strengthening governance and diversifying its business. The company will establish a new Legal Affairs Department...
COSMOS Pharmaceutical Posts Steady First-Half Growth and Confirms Full-Year Outlook
Jan 13, 2026
COSMOS Pharmaceutical reported consolidated net sales of ¥537.2 billion for the six months ended November 30, 2025, up 6.2% year on year, with operating profit rising 1.6% to ¥20.7 billion and profit attributable to owners of parent incr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.